S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Structure Therapeutics (GPCR) Stock Forecast & Price Target

$41.24
+0.67 (+1.65%)
(As of 03/1/2024 ET)

Structure Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$89.17
116.21% Upside
High Forecast$97.00
Average Forecast$89.17
Low Forecast$79.00
TypeCurrent Forecast
3/4/23 to 3/3/24
1 Month Ago
2/2/23 to 2/2/24
3 Months Ago
12/4/22 to 12/4/23
1 Year Ago
3/4/22 to 3/4/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$89.17$81.14$81.14$39.25
Predicted Upside116.21% Upside65.45% Upside65.45% Upside63.54% Upside
Get Structure Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.


GPCR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GPCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Structure Therapeutics Stock vs. The Competition

TypeStructure TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside116.21% Upside1,799.09% Upside6.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/27/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Belghiti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
11/15/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Outperform ➝ Market Outperform$90.00 ➝ $91.00+79.84%
10/26/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$58.00 ➝ $93.00+32.38%
10/3/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$40.00 ➝ $83.00+43.47%
10/2/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$50.00 ➝ $92.00+58.76%
9/29/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$46.00 ➝ $97.00+92.38%
9/29/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$50.00 ➝ $79.00+58.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:27 AM ET.












GPCR Price Target - Frequently Asked Questions

What is Structure Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Structure Therapeutics stock is Buy based on the current 5 buy ratings for GPCR. The average twelve-month price prediction for Structure Therapeutics is $89.17 with a high price target of $97.00 and a low price target of $79.00. Learn more on GPCR's analyst rating history.

Do Wall Street analysts like Structure Therapeutics more than its competitors?

Analysts like Structure Therapeutics more than other Medical companies. The consensus rating for Structure Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how GPCR compares to other companies.

Does Structure Therapeutics's stock price have much upside?

According to analysts, Structure Therapeutics's stock has a predicted upside of 57.66% based on their 12-month stock forecasts.

What analysts cover Structure Therapeutics?

Structure Therapeutics has been rated by Lifesci Capital in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:GPCR) was last updated on 3/3/2024 by MarketBeat.com Staff